Stock BYSI BEYONDSPRING INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases BeyondSpring Inc.

Equities

BYSI

KYG108301006

Delayed Nasdaq
Other stock markets
 11:11:17 29/04/2024 pm IST 		5-day change 1st Jan Change
2.22 USD +4.23% Intraday chart for BeyondSpring Inc. +5.21% +146.67%
12:23pm North American Morning Briefing : Investors Brace -2- DJ
22/04 North American Morning Briefing : Stock Futures -2- DJ

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
BeyondSpring Announces First Patient Dosed with Pembrolizumab, Plinabulin Plus Etoposide/Platinum in a Phase 2 Investigator-initiated Study of First-Line Extensive-Stage Small-Cell Lung Cancer
AQ
BeyondSpring Regains Compliance with Nasdaq Minimum Bid Price and Periodic Filing Requirements
AQ
BeyondSpring Receives Nasdaq Delinquency Notice Regarding Late Filing of Its Form 6-K
AQ
BeyondSpring Receives Nasdaq Notice Regarding Minimum Bid Price Requirements
AQ
BeyondSpring Presents Poster Highlighting Preclinical and Clinical POC Immunomodulating Activity of Plinabulin Inducing Dendritic Cell Maturation and Re-sensitization in Immunotherapy Refractory Tumors when Combined with Radiation and PD-1/PD-L1 Inhibitors
AQ
BEYONDSPRING AND PROFESSOR K. EISENMANN OF THE UNIVERSITY OF TOLEDO COLLEGE OF MEDICINE PRESENT POSTER HIGHLIGHTING PLINABULIN'S ANTI-CANCER EFFICACY IN PRIMARY AND RECURRENT GLIOBLASTOMA PATIENT DERIVED INVASIVE NEUROSPHERE MODELS
AQ
BeyondSpring and Professor K. Eisenmann of the University of Toledo College of Medicine Present Poster Highlighting Plinabulin’s Anti-cancer Efficacy in Primary and Recurrent Glioblastoma Patient Derived Invasive Neurosphere Models
AQ
BeyondSpring Regains Compliance with Nasdaq Minimum Bid Price Requirement
AQ
SEED THERAPEUTICS DISCLOSES NOVEL MOLECULAR GLUE IND CANDIDATE FOR CANCER AT 'TARGETED PROTEIN DEGRADATION THINK TANK' SYMPOSIUM
AQ
SEED Therapeutics Discloses Novel Molecular Glue IND Candidate for Cancer at “Targeted Protein Degradation Think Tank” Symposium
AQ
SEED Therapeutics, a BeyondSpring Subsidiary, Appoints Mr. Ko-Yung Tung to the Board of Directors
AQ
BeyondSpring Receives Nasdaq Notice Regarding Minimum Bid Price Requirements
AQ
BEYONDSPRING AND LEADING CANCER CENTER TO PRESENT POSTER AT SITC'S 38TH ANNUAL MEETING
AQ
BeyondSpring and Leading Cancer Center to Present Poster at SITC’s 38th Annual Meeting
AQ
BeyondSpring : Form 20-F T Form 40-F □ - Form 6-K
PU
BeyondSpring to Participate in the R.W. Baird’s 2023 Global Healthcare Conference
AQ
SEED Therapeutics, BeyondSpring Subsidiary, Appoints Jackson Tai to Board of Directors
AQ
BEYONDSPRING AND LEADING CANCER CENTER PRESENT POSTER HIGHLIGHTING PLINABULIN'S ABILITY TO REDUCE INFECTIOUS NEUTROPENIC FEVER FOR MULTIPLE MYELOMA PATIENTS UNDERGOING AHCT
AQ
BeyondSpring and Leading Cancer Center Present Poster Highlighting Plinabulin’s Ability to Reduce Infectious Neutropenic Fever for Multiple Myeloma Patients Undergoing AHCT
AQ
BeyondSpring and Leading Cancer Center to Present Poster at 2023 ASCO Annual Meeting
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. BYSI Stock
  4. News BeyondSpring Inc.
  5. Press Releases